← Eichor
Study identifier: NCT05970237 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

Condition: Diabetes Mellitus · Hypertension  ·  Sponsor: Boryung Pharmaceutical Co., Ltd

PhaseN/A
Planned participants9000
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension

This description comes directly from the study's public registry record.

Talk to the study team

Shinyoung Oh  ·  +82-2-708-8000  ·  syoh@boryung.co.kr

Always discuss trial participation with your own doctor first.

Locations (1)

Gachon University Gil Medical CenterIncheon, Namdong-gu, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05970237